[1]刘丽燕a,陈晓丹b,杨明夏c,等.外周血异常糖链糖蛋白检测对非小细胞肺癌患者治疗监测的意义[J].现代检验医学杂志,2017,32(01):103-105.[doi:10.3969/j.issn.1671-7414.2017.01.028]
　LIU Li-yana,CHEN Xiao-danb,YANG Ming-xiac,et al.Significance of Tumor Abnormal Protein in Peripheral Blood in the Therapeutic Monitoring of Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2017,32(01):103-105.[doi:10.3969/j.issn.1671-7414.2017.01.028]
点击复制

外周血异常糖链糖蛋白检测对非小细胞肺癌患者治疗监测的意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年01期
页码:
103-105
栏目:
论著
出版日期:
2017-01-25

文章信息/Info

Title:
Significance of Tumor Abnormal Protein in Peripheral Blood in the Therapeutic Monitoring of Non-Small Cell Lung Cancer
文章编号:
1671-7414(2017)01-103-03
作者:
刘丽燕a; 陈晓丹b; 杨明夏c; 周洪兴b
南京医科大学附属常州第二人民医院 a.输血科;
b.检验科;
c.呼吸科,江苏常州 213003
Author(s):
LIU Li-yana; CHEN Xiao-danb; YANG Ming-xiac; ZHOU Hong-xingb
a.Department of Blood Transfusion;
b.Department of Clinica Laboratory;
c.Department of Respiratory Medicine,Affiliated Changzhou 2nd Hospital of Nanjing Medical University,Jiangsu Changzhou 213003,China
关键词:
异常糖链糖蛋白;  非小细胞肺癌;  疗效监测
分类号:
R734.2; R730.43
DOI:
10.3969/j.issn.1671-7414.2017.01.028
文献标志码:
A
摘要:
目的 观察肿瘤异常糖链糖蛋白(TAP)对非小细胞肺癌(NSCLC)患者治疗监测的意义。方法 选取临床确诊为NSCLC的患者30例,采集其治疗前、治疗后半个月、一个月、三个月、六个月外周静脉血并涂片,用凝集法检测TAP,以最大凝聚物面积为衡量指标,评估其对NSCLC治疗监测的意义。同时收集30例健康体检者血作为对照组。结果 治疗前NSCLC患者TAP阳性率为86.67%,健康体检者TAP阳性率为3.33%,差异有统计学意义(χ2=140.3,P＜0.01); Ⅲ～Ⅳ期NSCLC患者TAP凝聚物面积[411(89,562)mm2]高于Ⅰ～Ⅱ期NSCLC患者[267(31,407)mm,差异有统计学意义(H=18.91,P＜0.05); 两组患者治疗后TAP凝聚物面积均开始降低,Ⅰ～Ⅱ期患者治疗一个月后凝聚物面积与治疗前差异有统计学意义(Z=-3.21,P＜0.01),Ⅲ～Ⅳ期患者治疗半个月后TAP凝聚物面积与治疗前差异有统计学意义(Z=-2.78,P＜0.05)。治疗三个月后,两组凝聚物面积均达最低水平,Ⅰ～Ⅱ期患者平均凝聚物面积下降至治疗前的21%,Ⅲ～Ⅳ期患者下降至治疗前的37%,且Ⅰ～Ⅱ期患者TAP凝聚物面积下降幅度高于Ⅲ～Ⅳ期患者,差异有统计学意义(χ2=6.22,P＜0.05)。结论 外周静脉血TAP检测NSCLC敏感性较高,可用于NSCLC患者的疗效监测,评估治疗效果。
Abstract:
Objective To observe the significance of tumorabnormal protein(TAP)in the therapeutic monitoring of non-small cell lung cancer(NSCLC).Methods Peripheral blood from 30 NSCLC patients were collected to make smears at the moment of pre-treatment,half a month,one month,3 months and 6 months after therapy.TAP was detected by coacervation method.The maximum area of condense was applied to estimate the level of TAP.Thirty healthy subjects were chose as control group.Results The positive rate of TAP in NSCLC patients was 86.67%,and 3.33% of healthy subjects were positive in TAP.The difference was statistically significant(χ2=140.3,P＜0.01).The condense area of TAP in patients with Ⅲ～Ⅳ stage of NSCLC [411(89,562)mm2] was significantly higher than those with Ⅰ～Ⅱstage NSCLC [267(31,407)mm2].The condense areas in both of two groups went down after treatment.A significant difference of condense area appeared in Ⅰ～Ⅱ stage of NSCLC patients a month after therapy as well as Ⅲ～Ⅳ stage of NSCLC patients half a month after treatment.The condense areas went to their lowestlevel 3 months after therapy.For Ⅰ～Ⅱ stage patients,the condense area fellto 21% compared to that before treatment,but for patients with Ⅲ～Ⅳ stage of NSCLC,37% of pre-treatment condense area were detected.TheⅠ～Ⅱ stage of NSCLCpatients had a greater decrease in condense area of TAP than the Ⅲ～Ⅳ stage patients by 3 months after treatment(χ2=6.22,P＜0.05).Conclusion Detection of TAP in peripheral blood had a high sensitivity forNSCLC,and is able to monitoring the treatment effect.

参考文献/References:

[1] 蒋贝兰,沙 杭.肺癌血清肿瘤标志物的研究现状及进展[J].天津医药,2014,42(4):393-395. Jiang BL,Sha H.Current study and progress of serum tumor markers in lung cancer[J].Tianjin Medical Journal,2014,42(4):393-395.
[2] 史 英,柳志宝,高敬华,等.肿瘤异常蛋白对消化道恶性肿瘤的表达及化疗疗效评价[J].中国综合临床,2015,31(12):1125-1127. Shi Y,Liu ZB,Gao JH,et al.Expression of tumor abnormal protein in digestive tract malignant tumor and its effect on chemotherapy[J].ClinicalMedicine of China,2015,31(12):1125-1127.
[3] 何 萍,徐昌维,单喜花,等.肿瘤异常蛋白对肺癌患者近期疗效的意义[J].河北中医,2014,36(12):1915-1916. He P,Xu CW,Shan XH,et al.The curative effect of tumor abnormal protein in lung cancer patients[J].Hebei Journal of Traditional Chinese Medicine,2014,36(12):1915-1916.
[4] 邱志远,陶 曙,雷 珍,等.肿瘤异常蛋白在胃肠肿瘤中的临床价值[J].癌症进展,2016,14(4):340-342. Qiu ZY,Tao S,Lei Z,et al.The clinical value of tumor abnormal protein in gastrointestinal tumors[J].Oncology Progress,2016,14(4):340-342.
[5] 王义霞,胡 涛,徐尊花,等.肿瘤异常蛋白检测系统在早期妇科恶性肿瘤筛查中的应用价值[J].中国实验诊断学,2016,20(5):745-747. Wang YX,Hu T,Xu ZH,et al.The application value of tumor abnormal protein diction system in the early stage of gynecological maliganat tumor screening[J].Chin J Lab Diagn,2016,20(5):745-747.
[6] 刘申香,童建东.肺癌的影像学筛查研究进展[J].中国医学影像学杂志,2014,22(12):958-960. Liu SX,Tong JD.Advances in imaging screening of lung cancer[J].Chinese Journal of Medical Imaging,2014,22(12):958-960.
[7] 杨兰平,黄汉生,陈慧华,等.非小细胞肺癌患者化疗前后血清CYFRA211,CEA,NSE,CA125,CA199水平的变化及临床意义[J].实用临床医药杂志,2014,18(17):40-43. Yang LP,Huang HS,Chen HH,et al.Clinical significance in changes of serum CYFRA211,CEA,NSE,CA125,CA199 levels before and after chemotherapy in patients with non-small cell lung cancer[J].Journal of Clinial Medicine inPractice,2014,18(17):40-43.

相似文献/References:

[1]陈 相a,陶国华a,周 峰a,等.叉头框蛋白J2在非小细胞肺癌组织 和癌旁组织中的表达及临床意义[J].现代检验医学杂志,2016,31(03):95.[doi:10.3969/j.issn.1671-7414.2016.03.026]
　CHEN Xianga,TAO Guo-huaa,ZHOU Fenga,et al.Expression and Its Clinical Significance of Forkhead Box J2 in Non-small Cell Lung Cancer Tissues and Paracancerous Tissues[J].Journal of Modern Laboratory Medicine,2016,31(01):95.[doi:10.3969/j.issn.1671-7414.2016.03.026]
[2]王芳胜,熊敦勇,寇辉,等.血清AFP，CEA，CA-199与TAP在肝癌诊断中的应用价值[J].现代检验医学杂志,2015,30(05):148.[doi:10.3969/j.issn.1671-7414.2015.05.047]
　WANG Fang-sheng,XIONG Dun-yong,KOU Hui,et al.Application Value of Serum AFP，CEA，CA-199 and TAP in the Diagnosis of Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(01):148.[doi:10.3969/j.issn.1671-7414.2015.05.047]
[3]张永庆a,尚立群a,苗 毅a,等.表皮生长因子受体基因突变与非小细胞肺癌病理的相关性分析[J].现代检验医学杂志,2017,32(06):78.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　ZHANG Yong-qinga,SHANG Li-quna,MIAO Yia,et al.Analysis of the Correlation between Mutations of the Epidermal Growth Factor Receptor Gene and Pathological of Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2017,32(01):78.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[4]喻 晶,李运雷,刘晓翌.非小细胞肺癌患者不同类型样本中表皮生长因子受体基因突变的差异研究[J].现代检验医学杂志,2018,33(04):31.[doi:10.3969/j.issn.1671-7414.2018.04.008]
　YU Jing,LI Yun-lei,LIU Xiao-yi.Detection of Epidermal Growth Factor Receptor Gene Mutation in Different Sample Types of 238 Patients with Non-small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):31.[doi:10.3969/j.issn.1671-7414.2018.04.008]
[5]林文科,吴吉芳,郑志昂.非小细胞肺癌患者血清miR-141及miR-224的表达及其临床意义[J].现代检验医学杂志,2018,33(02):46.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIN Wen-ke,WU Ji-fang,ZHENG Zhi-ang.Expression of Serum miR-141 and miR-224 in Patients with Non-Small Cell Lung Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(01):46.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[6]邝美华,陈意珊,石亚玲.血小板与淋巴细胞比值对非小细胞肺癌预后评估的Meta分析[J].现代检验医学杂志,2018,33(03):112.[doi:10.3969/j.issn.1671-7414.2018.03.028]
　KUANG Mei-hua,CHEN Yi-shan,SHI Ya-ling.Prognostic Value of Platelet to Lymphocyte Ratio in Non-Small Cell Lung Cancer:a Meta-analysis[J].Journal of Modern Laboratory Medicine,2018,33(01):112.[doi:10.3969/j.issn.1671-7414.2018.03.028]
[7]苗留飞,杨 阳,余柏增,等.三代EGFR-TKI奥希替尼(AZD9291)耐药细胞系建立及耐药标志预测分析[J].现代检验医学杂志,2019,34(05):28.[doi:10.3969/j.issn.1671-7414.2019.05.008]
　MIAO Liu-fei,YANG Yang,YU Bai-zeng,et al.Establishment of the Third Generation of EGFR-TKI Resistant CellLine and Resistance Gene Signature[J].Journal of Modern Laboratory Medicine,2019,34(01):28.[doi:10.3969/j.issn.1671-7414.2019.05.008]
[8]岳丹,王晓辉,付超,等.外周血异常糖链糖蛋白（TAP）检测对于肿瘤筛查及早期辅助诊断的意义[J].现代检验医学杂志,2020,35(05):62.[doi:10.3969/j.issn.1671-7414.2020.05.016]
　YUE Dan,WANG Xiao-hui,FU Chao,et al.Significance of Tumor Abnormal Protein (TAP) Peripheral Blood in the Detection of Tumor Screening and Early Auxiliary Diagnosis[J].Journal of Modern Laboratory Medicine,2020,35(01):62.[doi:10.3969/j.issn.1671-7414.2020.05.016]
[9]王　旋,崔立春,党升强.非小细胞肺癌放化疗联合靶向治疗对血清肿瘤标志物、免疫功能及CyclinD3水平影响的相关研究[J].现代检验医学杂志,2021,36(04):25.[doi:10.3969/j.issn.1671-7414.2021.04.006]
　WANG Xuan,CUI Li-chun,DANG Sheng-qiang.Effects of Radiotherapy and Chemotherapy Combined with Targeted Therapy onSerum Tumor Markers, Immune Function and CyclinD3 Level inNon-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2021,36(01):25.[doi:10.3969/j.issn.1671-7414.2021.04.006]

备注/Memo

备注/Memo:
作者简介:刘丽燕(1982-),女,学士,主管技师,研究方向:肿瘤标志物和免疫学检验,Tel:0519-81087091,E-mail:2860126468@qq.com。
更新日期/Last Update: 2017-01-20